Chronic administration of buprenorphine in combination with samidorphan produces sustained effects in olfactory bulbectomised rats and Wistar-Kyoto rats

J Psychopharmacol. 2019 Dec;33(12):1620-1627. doi: 10.1177/0269881119872203. Epub 2019 Sep 12.

Abstract

Background: The combination of buprenorphine, a partial mu-opioid receptor agonist and a functional kappa-opioid receptor antagonist, with samidorphan, a functional mu-opioid receptor antagonist, is being developed as an adjunct therapy for major depressive disorder, in order to harness the mood-enhancing effects of opioids without unwanted side-effects such as a risk of addiction. Acute and subacute administration of the combination of buprenorphine and samidorphan is effective in reducing forced swim immobility in the Wistar-Kyoto rat, but the chronic effects have not been examined.

Aims and methods: The purpose of this study was to assess if chronic (14-day) administration of buprenorphine (0.1 mg/kg, subcutaneous) alone or in combination with samidorphan (0.3 mg/kg, subcutaneous) maintains antidepressant-like activity in the olfactory bulbectomised rat model and the Wistar-Kyoto rat, two models that exhibit ongoing behavioural deficits in tests commonly used to study effects of antidepressants.

Results: Olfactory bulbectomised-induced hyperactivity was attenuated by chronic administration of buprenorphine alone and in combination with samidorphan, to that of sham control activity levels. Neither buprenorphine nor samidorphan altered stress-associated defecation in sham or olfactory bulbectomised rats in the open field. In Wistar-Kyoto rats, buprenorphine alone significantly reduced forced swim immobility and increased locomotor activity three hours post-final dosing. Buprenorphine plus samidorphan significantly reduced forced swim immobility without changing locomotor activity at this time point. Buprenorphine alone also significantly reduced forced swim immobility 24 h post-final dosing.

Conclusion: Chronic treatment of buprenorphine alone or buprenorphine plus samidorphan is effective in reversing behavioural deficits in distinct non-clinical paradigms. These non-clinical results complement the antidepressant effect of this combination observed in clinical studies.

Keywords: Opioids; Wistar-Kyoto; buprenorphine; forced swim test; olfactory bulbectomy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antidepressive Agents / administration & dosage*
  • Antidepressive Agents / pharmacology
  • Behavior, Animal / drug effects
  • Buprenorphine / administration & dosage*
  • Buprenorphine / pharmacology
  • Depression / drug therapy*
  • Disease Models, Animal
  • Drug Therapy, Combination
  • Locomotion / drug effects
  • Male
  • Naltrexone / administration & dosage
  • Naltrexone / analogs & derivatives*
  • Naltrexone / pharmacology
  • Narcotic Antagonists / administration & dosage
  • Narcotic Antagonists / pharmacology
  • Rats
  • Rats, Inbred WKY
  • Rats, Sprague-Dawley

Substances

  • Antidepressive Agents
  • Narcotic Antagonists
  • Buprenorphine
  • Naltrexone
  • 3-carboxamido-4-hydroxynaltrexone